Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year

• Published in: American journal of clinical dermatology Vol. 25; no. 2; pp. 327 - 332
• Main Authors: Hu, Wilson, Thornton, Michele, Livingston, Robert A.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.03.2024; Springer Nature B.V
• Subjects: Cancer therapies; Clinical trials; Dermatitis; Dermatitis, Atopic - drug therapy; Dermatology; Disease; Emollients - therapeutic use; FDA approval; Humans; Industrial safety; Infections; Inhibitor drugs; Janus Kinase Inhibitors; Kinases; Medical personnel; Medicine; Medicine & Public Health; Mortality; Nitriles - therapeutic use; Original; Original Research Article; Pericarditis; Pharmacology/Toxicology; Pharmacotherapy; Professionals; Pyrazoles; Pyrimidines; Rheumatoid arthritis; Skin cancer; Targeted cancer therapy; Thrombosis; Topical medication; United States; Vitiligo; United States; United States > US

Background Ruxolitinib cream is the first topical Janus kinase (JAK) inhibitor approved in the United States (US) for the treatment of mild to moderate atopic dermatitis and nonsegmental vitiligo. A postmarketing study with oral tofacitinib, approved for rheumatoid arthritis, triggered class warning...